David L. Huso, D.V.M., Ph.D., Dip ACVP
Diplomate, American College of Veterinary Pathology
Associate Professor, Department of Molecular and Comparative Pathobiology
& The Sidney Kimmel Comprehensive Cancer Center
Background and Training
Dr. Huso completed his Ph.D. training at Johns Hopkins University School of Medicine focusing on molecular pathogenesis and mechanisms of disease while completing an NIH sponsored postdoctoral fellowship in comparative pathology. After his fellowship he achieved board certification from the American College of Veterinary Pathology and received a faculty appointment in the Department of Molecular and Comparative Pathobiology. He initially set up his own research laboratory in Comparative Pathobiology at the Asthma and Allergy Center at the Johns Hopkins Bayview Research Campus. He subsequently moved his laboratory back to the JHMI campus in the Department of Molecular and Comparative Pathobiology.
Dr. Huso mentors a number of individuals both inside and outside the department including students, fellows and staff with research interests in the molecular pathogenesis and treatment of genetic diseases including cancer. He also is director of a graduate school class covering the basics of comparative histology and the development of humanized and engineered mouse models. His research integrates molecular techniques with mouse models to facilitate the movement of preclinical basic science discoveries to the clinic to benefit patients. In addition, he devotes a portion of his time to pathology training of fellows in the department supported by an NIH training grant and provides diagnostic pathology in support of the mouse research colonies at JHU.
Dr. Huso’s laboratory uses the mouse as a genetic system in which to determine mammalian gene function and to elucidate the details of the molecular pathogenesis and treatment of human diseases. This system, along with emerging novel molecular approaches, provides a platform for discovery of underlying disease mechanisms as well as rapid validation of novel targeted therapies using a rational approach based on molecular mechanisms of diseases. Accurate and predictive mouse models are developed and used extensively, not only in discovery of mechanisms and evaluation of efficacy of emerging therapeutic approaches, but also to determine the safety of new therapeutics. Dr. Huso’s research laboratory is made up of persons with diverse backgrounds including students, fellows, assistants and associates with backgrounds in veterinary and human medicine. His current areas of research are highlighted by his publications and includes modeling mechanisms of autoimmune-mediated fibrotic diseases (Stiff Skin Syndrome and Systemic Sclerosis) as well as stem cells and novel therapeutic approaches in IBD and cancer.
Relevant recent articles
- Gallo EM, Loch DC, Habashi JP, Calderon JF, Chen Y, Bedja D, van Erp C, Gerber EE, Parker SJ, Sauls K, Judge DP, Cooke SK, Lindsay ME, Rouf R, Myers L, ap Rhys CM, Kent KC, Norris RA, Huso DL, Dietz HC. Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. 2014. J Clin Invest. 124:448-460. PMCID: PMC3871227
- Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, Rhee KJ, Ortega G, Huso DL, Pardoll D, Housseau F, Sears CL. Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. 2014. Inflamm Bowel Dis. 20:821-834. PMID: 24704822
- Outeda P, Huso DL, Fisher SA, Halushka MK, Kim H, Qian F, Germino GG, Watnick T. Polycystin signaling is required for directed endothelial cell migration and lymphatic development. 2014. Cell Reports 7:634-644. PMID: 24767998
- Karim BO, Huso DL. Mouse models for colorectal cancer. 2013. Am J Cancer Res. 2013. 3:240-250. PMCID: PMC3696531
- Karim BO, Rhee KJ, Liu G, Zheng D, Huso DL. Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc(-/+) mice. 2013. BMC Cancer. 13:157. PMCID: PMC3618006
- Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, Dietz HC. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. 2013. Nature. 503:126-130. PMCID: PMC3992987
- Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S. A nanoparticle formulation that selectively transfects metastatic tumors in mice. 2013. PNAS. 110:14717-14722. PMCID: PMC3767543
- Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. 2007. Nat Med. 13:1490-1495. PMCID: PMC2302790
- Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. 2006. Science. 312:117-121. PMCID: PMC1482474
- Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, Huso D, Greider CW. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. 2005. Cell 123:1121-1131. PMID: 16360040